TRYSUL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trysul, and when can generic versions of Trysul launch?
Trysul is a drug marketed by Savage Labs and is included in one NDA.
The generic ingredient in TRYSUL is triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole). There are five drug master file entries for this compound. Additional details are available on the triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole) profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRYSUL?
- What are the global sales for TRYSUL?
- What is Average Wholesale Price for TRYSUL?
Summary for TRYSUL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| DailyMed Link: | TRYSUL at DailyMed |
US Patents and Regulatory Information for TRYSUL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Savage Labs | TRYSUL | triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole) | CREAM;VAGINAL | 087887-001 | Jul 23, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
